5 Late-Breaking Clinical Trials in Obesity to Watch at the ADA 85th Scientific Sessions, June 20-24, 2025
Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.
The American Diabetes Association’s 85th Scientific Sessions, taking place June 20–24 in Chicago, will feature newly compiled data from phase 2 and 3 trials of the next generation of obesity pharmacotherapy. Among the hundreds of educational and scientific sessions will be explorations of innovations in weight-loss treatment for individuals with and without type 2 diabetes (T2D), as well as progress in use of therapies successful for cardiometabolic disease in people with T2D in individuals with T1D.
Among the most anticipated late-breaking presentations are pivotal trial results for:
- A once-monthly injectable GLP-1 receptor agonist (GLP-1 RA) for obesity;
- A nonpeptide oral GLP-1 RA—potentially offering a novel oral alternative to injections;
- A dual-therapy agent pairing a GLP-1 RA with a second compound designed to maximize fat loss while maintaining lean muscle mass.
The short slide show above provides 5 snapshots of the molecules, the specific studies to be presented, and recaps of previous research along with comments from clinical trial authors.
Click here for additional information or to register for the ADA 85 Scientific Sessions.
